Phaseline

Targets › RLN2

RLN2 (Prorelaxin H2 [Cleaved into: Relaxin B chain; Relaxin A chain]): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2026.

Relaxin is an ovarian hormone that acts with estrogen to produce dilatation of the birth canal in many mammals. May be involved in remodeling of connective tissues during pregnancy, promoting growth of pubic ligaments and ripening of the cervix. (UniProt, P04090)

Open in Phaseline: the race on RLN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cambridge University Hospitals NHS Foundation TrustRelaxin
RLN2-encoded endogenous peptide hormone that binds to G protein-coupled receptor RXFP1
RLN2, RXFP1Phase 2Cardiovascular DiseasesDec 2026

Conditions

Cardiovascular Diseases (1)

Modalities

small molecule (1)

Companies

Cambridge University Hospitals NHS Foundation Trust (1)

Related targets

RXFP1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.